Skip to content
Sign in
StableHealthReported 2026-11-20 23:46

Isomorphic Labs and MSD announce strategic AI-driven drug discovery collaboration

Isomorphic Labs and MSD (Merck) announced a strategic collaboration to discover small-molecule therapeutic candidates targeting a strategically important oncology indication. Isomorphic Labs will apply its IsoDDE AI platform for in silico predictions and molecular design, while MSD will lead preclinical and clinical development, manufacturing, and commercialization.

In depthRead the in-depth story

Why it matters. The partnership combines Isomorphic Labs' AI drug design capabilities with MSD's proprietary data and biopharmaceutical expertise to accelerate the discovery of new oncology candidates, potentially reshaping therapeutic development for…

01

Who and what it touches

Alphabetinvests inGreenoaksfinancesartificial intelligen…usesLondonlocated inbioresilienceenablesIsoDDEproducesMSDpartners withLillyservesIsomorphic Labs

Into Isomorphic Labs

From Isomorphic Labs

Each line is a relation with evidence behind it, drawn in the direction it points. A line shows that two things are connected, not how far this change reaches.

02

Evidence

  • PPR Newswire news releasesCompany2026-11-20 23:46
    Schon heute leisten wir Pionierarbeit in der Forschung, um innovative Gesundheitslösungen zu entwickeln, welche die Prävention und Behandlung von Erkrankungen bei Menschen und Tieren voranbringen.
    View source
  • PPR Newswire news releasesCompany2026-11-20 03:27
    Isomorphic Labs effectuera des prédictions *in silico* et fournira des conceptions moléculaires, en appliquant son moteur de conception de médicaments propriétaire (IsoDDE) intégrant des ensembles de données propriétaires de haute qualité sélectionnés fournis par MSD aux fins de…
    View source